Health Care · Biological Products, (No Diagnostic Substances) · OTC · CIK 882361 · FYE Dec 31 · Prices AT CLOSE 2026-07-02 (USD) Last $1.69 · 1Y +89.9% · Off 52W high −8.6% · Vol (1Y) 84.1% Price2025-04-02 → 2026-07-02 APTOF close: $2.01 on 2025-04-02 to $1.69 on 2026-07-02. Split-adj closes · 240 of 678 · price returnⓘ At a glance | Short interest0.1% of sh out | | Days to cover2.0d | | 13F net flow (QoQ)+0.00% | | Top-10 13F concentration100.0% | | Next report (est.)2026-11-13 |
SI 2026-06-30 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Sales (TTM)$0 | | Earnings (TTM)-$27.6M |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD+14.2% | | 1Y+89.9% | | 3Y−15.9% | | 5Y−15.9% | | Since incept. (ann.)+29.2% |
Total return · from 2016-07-11ⓘ Risk | Ann. volatility (1Y)84.1% | | Ann. volatility (3Y)96.7% | | Sharpe (1Y)1.20 | | Sharpe (3Y)0.32 | | Max drawdown (1Y)−45.4% | | Max drawdown (3Y)−73.3% | | Beta (3Y vs SPY)−1.31 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| DRW Securities, LLC | 19,761 | $32,921 | 0.77% | +0.0% | | Gleason Group, Inc. | 4,206 | $7,024 | 0.16% | +0.0% | | Farther Finance Advisors, LLC | 10 | $17 | 0.00% | +0.0% | | CALDWELL SUTTER CAPITAL, INC. | 2 | $3 | 0.00% | +0.0% |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-05-13 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-03-31 | 2026-05-13 | −$2.99 | — | $0 | — | | 2025-12-31 | 2026-03-31 | — | — | $0 | — | | 2025-09-30 | 2025-11-13 | −$2.01 | — | $0 | — | | 2025-06-30 | 2025-08-13 | −$2.76 | — | $0 | — |
As-reported XBRL · next 2026-11-13 est.ⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
|
